Evoke Pharma Schedules Webcast and Conference Call for Third Quarter 2014 Financial Results
GlobeNewswire - Thu Nov 06, 7:42AM CST
Evoke Pharma, Inc. (Nasdaq:EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) diseases, today announced that it will issue its financial results for the Third Quarter of 2014 on Thursday, November 13, 2014, after the close of the market.
EVOK: 6.70 (+0.08)
Nasdaq stocks posting largest percentage increases
AP - Thu Oct 30, 5:02PM CDT
NEW YORK (AP) — A look at the 10 biggest percentage gainers on Nasdaq at the close of trading:
IMDZ: 30.06 (-0.03), ABMD: 32.13 (+0.47), BGFV: 12.95 (+0.27), RDCM: 8.80 (+0.12), AMED: 24.79 (-0.38), MRCY: 13.51 (-0.18), OMER: 17.37 (+0.09), ESBF: 18.66 (+0.03), EVOK: 6.70 (+0.08), IQNT: 17.14 (-0.14), KONA: 22.76 (-0.03), TQNT: 22.07 (-0.82), LAKE: 13.29 (+0.42), SAJA: 5.79 (-0.61)
Evoke Pharma completes enrollment of ECG Study of EVK-001 for diabetic gastroparesis ahead of schedule
M2 - Wed Sep 10, 6:22AM CDT
Pharmaceutical company Evoke Pharma (NasdaqCM:EVOK) disclosed on Tuesday that it has completed the enrollment in its thorough ECG (electrocardiogram) (QT) study of its lead product candidate EVK-001.
EVOK: 6.70 (+0.08)
Evoke Pharma Announces the Completion of Enrollment in Its Thorough ECG Study for EVK-001
GlobeNewswire - Tue Sep 09, 7:30AM CDT
Evoke Pharma, Inc. (Nasdaq:EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) diseases, today announced that it has completed enrollment in its thorough ECG (QT) study of EVK-001, the Company's lead product candidate. EVK-001 is currently in a Phase 3 clinical trial for the relief of symptoms associated with acute and recurrent gastroparesis in women with diabetes mellitus.
EVOK: 6.70 (+0.08)
Evoke Pharma to Present at the Aegis Capital Corp. 2014 Healthcare & Technology Conference
GlobeNewswire - Thu Sep 04, 7:35AM CDT
Evoke Pharma, Inc. (Nasdaq:EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) diseases, today announced that Dave Gonyer, CEO, will present a corporate overview at the Aegis Capital Corp. 2014 Healthcare & Technology Conference, being held September 10-13, 2014 at The Encore at The Wynn in Las Vegas, Nevada. The Company is scheduled to present on Thursday, September 11, 2014 at 2:00pm PT. A copy of the corporate overview will be posted to the company's website following the presentation.
EVOK: 6.70 (+0.08)
Evoke Pharma Reports Second Quarter 2014 Results
GlobeNewswire - Wed Aug 13, 3:01PM CDT
Evoke Pharma, Inc. (Nasdaq:EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) diseases, today announced its financial results for the second quarter ended June 30, 2014.
EVOK: 6.70 (+0.08)
Evoke Pharma Announces Initiation of a Thorough ECG (QT) Study for EVK-001
GlobeNewswire - Tue Aug 12, 4:42PM CDT
Evoke Pharma, Inc. (Nasdaq:EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) diseases, today announced the initiation of its thorough ECG (QT) study of the Company's lead product candidate, EVK-001, which is currently in a Phase 3 clinical trial for the relief of symptoms associated with acute and recurrent gastroparesis in women with diabetes mellitus.
EVOK: 6.70 (+0.08)
Nasdaq stocks posting largest volume decreases
AP - Tue Aug 05, 5:06PM CDT
NEW YORK (AP) — A look at the 10 biggest volume decliners on Nasdaq at the close of trading:
MCBK: 19.14 (+0.08), EVOK: 6.70 (+0.08), SBBX: 10.00 (-0.05), THRD: 40.87 (-1.08), NECB: 6.98 (+0.03), CBIN: 26.50 (-0.25), AMIC: 10.40 (-0.35), BRID: 7.75 (-0.50), SLTC: 5.84 (-0.20)
Evoke Pharma Schedules Webcast and Conference Call for Second Quarter 2014 Financial Results
GlobeNewswire - Wed Jul 30, 7:40AM CDT
Evoke Pharma, Inc. (Nasdaq:EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) diseases, today announced that it will issue its financial results for the second quarter of 2014 on Wednesday, August 13, 2014, after the close of the market.
EVOK: 6.70 (+0.08)
Evoke Pharma Reports Fourth Quarter and Year End 2013 Results
GlobeNewswire - Tue Mar 25, 3:30PM CDT
Evoke Pharma, Inc. (Nasdaq:EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) diseases, today announced its financial results for the fourth quarter and year ended December 31, 2013.
EVOK: 6.70 (+0.08)
Evoke Pharma Schedules Webcast and Conference Call for Fourth Quarter 2013 Financial Results
GlobeNewswire - Mon Mar 10, 9:02AM CDT
Evoke Pharma, Inc. (Nasdaq:EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) diseases, today announced that it will issue its financial results for the Fourth Quarter of 2013 on Tuesday, March 25, 2014, after the close of the market.
EVOK: 6.70 (+0.08)
Evoke Pharma to Present at 26th Annual ROTH Conference
GlobeNewswire - Tue Mar 04, 7:30AM CST
Evoke Pharma, Inc. (Nasdaq:EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) diseases, today announced that its President and Chief Executive Officer, Dave Gonyer, R.Ph., will be presenting at the 26 Annual ROTH Conference, being held March 10-12, 2014 at the Ritz-Carlton in Dana Point, California.
EVOK: 6.70 (+0.08)